Sirukumab

Sirukumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	IL6
Clinical data
ATC code	L04AC15 (WHO) ;
Identifiers
CAS Number	1194585-53-9 ;
DrugBank	DB11803 ;
ChemSpider	none;
UNII	640443FU93;
KEGG	D10080;
Chemical and physical data
Formula	C6450H9926N1690O1998S46
Molar mass	144588.95 g·mol−1
	(what is this?) (verify)

Sirukumab (INN, USAN) (developmental code name CNTO-136, tentative brand name Plivensia) is a human monoclonal antibody designed for the treatment of rheumatoid arthritis.^[1] It acts against the proinflammatory cytokine Interleukin 6 (IL-6).^[2]

Sirukumab is currently under development by Johnson & Johnson's subsidiary Centocor.^[3]

^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Sirukumab" (PDF). American Medical Association.
^ Bartoli F, Bae S, Cometi L, Matucci Cerinic M, Furst DE (July 2018). "Sirukumab for the treatment of rheumatoid arthritis: update on sirukumab, 2018". Expert Review of Clinical Immunology. 14 (7): 539–547. doi:10.1080/1744666X.2018.1487291. PMID 29925278. S2CID 49330982.
^ Cite error: The named reference Ph2 was invoked but never defined (see the help page).

[1] "Statement On A Nonproprietary Name Adopted By The USAN Council: Sirukumab" (PDF). American Medical Association.

[pmid29925278-2] Bartoli F, Bae S, Cometi L, Matucci Cerinic M, Furst DE (July 2018). "Sirukumab for the treatment of rheumatoid arthritis: update on sirukumab, 2018". Expert Review of Clinical Immunology. 14 (7): 539–547. doi:10.1080/1744666X.2018.1487291. PMID 29925278. S2CID 49330982.

[Ph2-3] Cite error: The named reference Ph2 was invoked but never defined (see the help page).

[1]

[2]

[3]